RxDoctor Payments Data

Kathleen Ingle

Family · Cannon Falls, MNNPI 1811949266

Payments from drug & device makers

$1,390in general payments, 2019–2025

Across 49 payments — averaging $28.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$495
  • Takeda Pharmaceuticals U.S.A., Inc.$344
  • Johnson & Johnson$152
  • Ardelyx, Inc.$136
  • Janssen Scientific Affairs, LLC$125
  • Bristol Myers Squibb$109
  • plus $29 from 1 others

What the payments were for

  • Food & beverage$1,390100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,390 in reported general payments places this provider in the 90th percentile of 1,121 family providers in Minnesota.

See all family providers in Minnesota

Medicare billing

Part B allowed, 2024
$71,449
Medicare patients
283
Services billed
3,944

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin21$46,721
LinzessLinaclotide17$11,583
Budesonide DrBudesonide59$5,587
Budesonide EcBudesonide16$2,395
Colestipol Hcl32$1,376
Neomycin Sulfate44$1,064
CholestyramineCholestyramine (With Sugar)24$867
Fluconazole23$767
Famotidine62$729
Omeprazole84$728
Pantoprazole Sodium46$506
Nystatin21$489
Ondansetron OdtOndansetron20$447
Doxycycline Hyclate40$423
Metronidazole37$355

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$495$11,58317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,121 family providers in Minnesota.

Other family in Cannon Falls

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →